Substance / Medication

Eplontersen

Overview

Active Ingredient
eplontersen
RxNorm CUI
2671939

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A review of Eplontersen use in hereditary transthyretin amyloidosis.
Sama Jacob, Khatri Wasi, Markus Nathan et al. · Neurodegener Dis Manag · 2025
PMID: 40884201Review
A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Olatunji Gbolahan, Kokori Emmanuel, Abraham Israel Charles et al. · Medicine (Baltimore) · 2024
PMID: 38941378ReviewFull text (PMC)
Eplontersen: First Approval.
Nie Tina · Drugs · 2024
PMID: 38413492ReviewFull text (PMC)
Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis.
Binte Anwar Insa, Furqan Ahmed Iqra, Mahmood Fariha et al. · Ann Med Surg (Lond) · 2025
PMID: 40109604OtherFull text (PMC)
Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis.
Wixner Jonas, Conceição Isabel, Berk John L et al. · Amyloid · 2025
PMID: 41147681Other
Eplontersen: a promising breakthrough in treating hereditary transthyretin amyloidosis-related polyneuropathy.
Qazi Muhammad Saeed, Tariq Muhammad Burhan, Farhan Kanza et al. · Ann Med Surg (Lond) · 2024
PMID: 39118766OtherFull text (PMC)
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
Masri Ahmad, Maurer Mathew S, Claggett Brian L et al. · J Card Fail · 2024
PMID: 38065307Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eplontersen (substance)
SNOMED CT
44076011000001103
UMLS CUI
C5421141
RxNorm CUI
2671939

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.